This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ReFacto Antihemophilic Factor

Pfizer Inc.

Drug Names(s): moroctocog alfa, Refacto AF, Recombinant Coagulation Factor VIII

Description: ReFacto Antihemophilic Factor (Recombinant) is a purified protein produced by recombinantDNA technology for use in therapy of factor VIII deficiency. ReFacto is a glycoprotein with anapproximate molecular mass of 170 kDa consisting of 1438 amino acids. It has an amino acidsequence that is comparable to the 90 + 80 kDa form of factor VIII, and post-translationalmodifications that are similar to those of the plasma-derived molecule. ReFacto has in vitrofunctional characteristics comparable to those of endogenous factor VIII.

Deal Structure: Biovitrum and Pfizer
ReFacto was originally developed by Biovitrum's organization while this was part of Pharmacia. The drug was sold to Wyeth in 1997. Biovitrum gains royalties and has co-promotion rights in the Middle East and Nordic regions.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.

In February 2012, Sobi announced that Sobi and Pfizer have extended their supply agreement for ReFacto AF/XYNTHA until 31 December 2020, with an option to be further renewed. The previous agreement was due to expire in 2015. In a separate agreement, Sobi and Pfizer also agreed that Sobi would return the co-promotion rights for ReFacto and BeneFIX in the Nordic region to Pfizer as of 15 February 2012 in exchange for a payment to...See full deal structure in Biomedtracker

Partners: Swedish Orphan Biovitrum


ReFacto Antihemophilic Factor News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug